Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Other Non-Current Assets (2016 - 2025)

Dare Bioscience (DARE) has disclosed Other Non-Current Assets for 11 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets rose 87.03% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Sep 2025, up 87.03%, and an annual FY2024 reading of $1.1 million, down 4.55% over the prior year.
  • Other Non-Current Assets was $1.0 million for Q3 2025 at Dare Bioscience, down from $1.1 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.3 million in Q1 2022 and bottomed at $10502.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $831126.4, with a median of $799327.0 recorded in 2023.
  • The sharpest move saw Other Non-Current Assets plummeted 97.84% in 2022, then soared 10978.62% in 2023.
  • Year by year, Other Non-Current Assets stood at $485120.0 in 2021, then tumbled by 97.84% to $10502.0 in 2022, then skyrocketed by 10978.62% to $1.2 million in 2023, then decreased by 4.55% to $1.1 million in 2024, then decreased by 8.3% to $1.0 million in 2025.
  • Business Quant data shows Other Non-Current Assets for DARE at $1.0 million in Q3 2025, $1.1 million in Q2 2025, and $1.1 million in Q1 2025.